KalVista Highlights Real-World Data on HAE Treatments and Patient Experiences at EAACI Congress

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the European Academy of Allergy and Clinical Immunology Congress 2024 that took place in Valencia, Spain.

The following presentations occurred at EAACI 2024:

• Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated? Cristine Radojicic, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina, USA. (Flash Talks Session)
  • For 50% of US survey respondents with HAE, their untreated attack progressed in severity while 25% of attacks migrated to other anatomic locations including the throat
  • Common reasons for not treating were desire to save injectable on-demand treatment for a severe attack, presumption the attack would stay mild, wanting to avoid needle pain or injection burning, stinging, or pain, and not having on-demand treatment with them
• Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers Rashmi Jain, Consultant in Clinical Immunology, Oxford University Hospital Trust, Oxford, UK. (Poster presentation)
  • 63% of UK survey participants reported their perception of time to treatment for HAE attacks as "early" despite only 14% treating in less than one hour
  • Common barriers to early on-demand treatment included the belief that the attack was going to remain mild and wanting to save injectable on-demand treatment for a severe attack
• Anxiety Associated with On-Demand Treatment for Hereditary Angioedema Attacks Patrick Yong, Frimley Health NHS Foundation Trust, Frimley, UK. (Poster presentation)
  • Almost half of UK survey participants reported moderate to extreme anxiety when anticipating use of injectable on-demand therapy to treat an attack
  • Top reasons for feeling anxious were desire not to ‘waste' on-demand treatment, uncertainty about how long the treatment would take to begin working, and finding a vein for IV infusion
• Patient-Reported Benefits of Early On-demand Treatment of HAE Attacks Hilary Longhurst, Auckland City Hospital, Te Toka Tumai, and University of Auckland, Auckland, New Zealand. (Poster presentation)
  • Results from this analysis highlight that survey respondents with HAE who treat their attacks early (<1 hour) are more likely to carry their on-demand treatment with them and treat more attacks overall compared with those who delay treatment (90.3% vs. 72.6%)
  • People living with HAE who treat their attacks early also recover more quickly from HAE attacks (1.4 hours vs 2.9 hours for those who waited ≥1 hour to treat), achieve full recovery earlier (1.3 vs 1.9 days), and feel less anxious when anticipating on-demand treatment
• Treatment of HAE Attacks with Anticipated Future Oral On-demand Therapies as Reported by Patients Anna Valerieva, Medical University of Sofia, Sofia, Bulgaria. (Poster presentation)
  • Survey respondents reported that they anticipated carrying an oral on-demand treatment 95.1% of the time compared with 63.9% with parenteral on-demand treatment; they would treat 88.5% of their attacks with an oral on-demand treatment compared with 80.3% with parenteral on-demand treatment
  • Of the respondents who thought they would treat attacks earlier with a pill vs. an injectable, 80% reported that they would have less anxiety when anticipating using an oral on-demand treatment
• Attack Characteristics in Patients with Hereditary Angioedema Receiving Non-Androgen Long-term Prophylaxis William Lumry, Allergy and Asthma Research Associates, Dallas, Texas, United States. (Flash Talks session)
  • In patients using non-androgen LTP, 68% of patients reported their most recent attack as moderate to very severe; 19.6% of these attacks involved laryngeal swelling and 12% required an ER visit or hospitalization
  • Only 55% of patients reported all their attacks to their physicians, which may have resulted in underestimation of attacks while receiving non-androgen LTP
• Unmet Needs Associated with Non-androgen Long-term Prophylaxis (LTP) Therapies for HAE William Lumry, Allergy and Asthma Research Associates, Dallas, Texas, United States. (Poster presentation)
  • Despite the availability of non-androgen LTPs, their use is associated with a high treatment burden
  • Lack of efficacy and gastrointestinal issues were the most common issues reported by physicians for patients using oral LTP; route of administration, discomfort, and frequent dosing schedule were the most common issues reported by physicians for patients using injectable LTPs
• A Sensitive and Specific Assay to Characterize Plasma Kallikrein Activity in Plasma from Hereditary Angioedema (HAE) Patients: Daniel Lee, KalVista Pharmaceuticals Inc., Cambridge, MA, USA. (Oral Abstract Session)
  • Outlines substantial progress on a sensitive and specific PKa assay that could be useful to characterize the level of PKa activity in plasma samples from PKa-mediated diseases, including patients diagnosed with HAE with normal C1 esterase inhibitor (nC1-INH-HAE)